Phase 4 N=30 Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine
Hypertension · Diabetes Mellitus
Primary: Endothelial Function — 9.4; 8.8 percentage of maximal vasodilation — p=0.616
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=252 OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.
Kidney Transplantation
Primary: Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR) Before Week 12 or Acute Subclinical Rejection on Protocol Biopsy at Week 12 — 24.2; 19.8 percentage…
N/A N=30 Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic
Colic · Inflammation
Primary: Daily Average Crying and Fussing Duration According to Barr Diary Records — 111; 133 minutes
Phase 3 N=329 A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Disease, Hodgkin
Primary: Progression-free Survival by Independent Review — 42.9; 24.1 months — p=0.001
N/A N=40 Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass
Heart Disease Congenital Complex
Primary: Incidence of Low Cardiac Output Syndrome (LCOS) — 57; 26 percentage of patients — p=0.049
Phase 2 N=36 Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria — 25.0 percentage of participants responding — p=0.0027
Phase 2 N=22 R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
Lymphoma
Primary: Progression-free Survival Rate — 91; 78; 69 percentage of participants
Phase 3 N=1,588 Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously…
Phase 3 N=467 Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.05; -1.36 percentage of glycosylated haemoglobin
Phase 3 N=144 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Disease-free Survival — 8.87; 5.26 months — p=0.026
N/A N=120 A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
Congestive Heart Failure · Chronic Obstructive Pulmonary Disease · Cirrhosis
Primary: Presence of Discussions About End of Life Care Goals/Wishes — 13; 8 participants — p=.77
Phase 3 N=248 A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
Atrial Fibrillation
Primary: Number of Participants With Incidence of Post-Procedure Major Bleeding Events — 0; 0; 0; 1 Participants
N/A N=242 Patient Controlled Epidural Analgesia Versus Local Infiltration Analgesia Following Knee Arthroplasty
Osteoarthritis
Primary: Proportion of Patients Discharged From Rehabilitation by Day Four — 77; 82 percentage of patients — p=0.332
Phase 4 N=230 Treatment of Vitamin D Insufficiency
Vitamin D Deficiency
Primary: Intestinal Calcium Absorption — 0.200; 0.217; 0.183; 0.206 Total Fractional Calcium Absorption
N/A N=80 Visual Assessment of DAILIES® AquaComfort Plus® for Astigmatism as Compared to 1-DAY ACUVUE® MOIST® for Astigmatism
Astigmatism
Primary: High Contrast Time Controlled Visual Acuity (TCVA) at Day 10 — 0.02; 0.04 VA units